CICCOCIOPPO, Rachele, Sara BOZZINI, Elena BETTI, Venerina IMBESI, Catherine KLERSY, Lucia LAKYOVA SUKOVSKA, Lukas SUKOVSKY, Jozef BENACKA, Peter KRUŽLIAK, Gino Roberto CORAZZA, Antonio DI SABATINO and Colomba FALCONE. Functional polymorphisms of the receptor for the advanced glycation end product promoter gene in inflammatory bowel disease: a case-control study. Clinical and Experimental Medicine. Milan: SPRINGER-VERLAG ITALIA SRL, 2019, vol. 19, No 3, p. 367-375. ISSN 1591-8890. Available from: https://dx.doi.org/10.1007/s10238-019-00562-x.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Functional polymorphisms of the receptor for the advanced glycation end product promoter gene in inflammatory bowel disease: a case-control study
Authors CICCOCIOPPO, Rachele (380 Italy, guarantor), Sara BOZZINI (380 Italy), Elena BETTI (380 Italy), Venerina IMBESI (380 Italy), Catherine KLERSY (380 Italy), Lucia LAKYOVA SUKOVSKA (703 Slovakia), Lukas SUKOVSKY, Jozef BENACKA (703 Slovakia), Peter KRUŽLIAK (703 Slovakia, belonging to the institution), Gino Roberto CORAZZA (372 Ireland), Antonio DI SABATINO (380 Italy) and Colomba FALCONE (380 Italy).
Edition Clinical and Experimental Medicine, Milan, SPRINGER-VERLAG ITALIA SRL, 2019, 1591-8890.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30219 Gastroenterology and hepatology
Country of publisher Italy
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.644
RIV identification code RIV/00216224:14110/19:00111780
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s10238-019-00562-x
UT WoS 000475560900010
Keywords in English Gene polymorphisms; Inflammatory bowel disease; RAGE
Tags 14110121, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 24/1/2020 14:44.
Abstract
The receptor for the advanced glycation end products (RAGE) is a multiligand transmembrane receptor involved in chronic inflammation whose specific polymorphisms of the promoter gene were found to increase its transcriptional activity. We investigated the association of both allelic and genotypic -374T/A and -429T/C polymorphisms with inflammatory bowel disease. The STREGA guidelines were applied for planning and reporting. We enrolled 133 patients with Crohn's disease (CD), 149 with ulcerative colitis (UC), and 128 blood donors. Genomic DNA was extracted from peripheral blood leukocytes collected from each patient and control. RAGE polymorphisms were analyzed by PCR-restriction fragment length polymorphism assay. The Hardy-Weinberg equilibrium was first assessed, and then, the Kruskal-Wallis test and the Fisher exact test were used for etiologic group comparisons. Distribution of patients' characteristics across genotypes was evaluated by the Fisher exact test, while that across alleles was analyzed with a probit model. A 2-sided value of p<0.05 was considered significant. Following the evidence of the Hardy-Weinberg equilibrium, we found a higher prevalence of the allele A of the -374T/A haplotype in UC (p=0.043), and of the allele C of the -429T/C haplotype in CD (p<0.001) with respect to the other groups. Moreover, the homozygous AA genotype of the -374T/A polymorphism resulted associated with late onset of CD, while its TT genotype with early onset (p=0.049). The allele C of the 429T/C haplotype was associated with early onset of UC (p=0.03), while a higher frequency of the heterozygous TC haplotype was found in those with pancolitis (p=0.026). The differing distribution of these polymorphisms in healthy donors and CD/UC patients suggests a role in the development and outcome of these pathological conditions.
PrintDisplayed: 23/8/2024 09:50